D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease

International Journal of Neuropsychopharmacology

Volumn 15, Issue 4, 2012, Pages 543-549

  Gelfin, Evgenia ^a,b   Kaufman, Yakir ^a,b   Korn Lubetzki, Isabelle ^c   Bloch, Boaz ^d,e   Kremer, Ilana ^d,e   Javitt, Daniel C ^f   Heresco Levy, Uriel ^a,b  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d HAEMEK MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f NEW YORK UNIVERSITY   (United States)

Author keywords

D serine; NMDAR; PD; treatment efficacy

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; SERINE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SERINE; SEVERITY OF ILLNESS INDEX;

EID: 84862680877     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001015     Document Type: Article

References (25)

1. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, et al. (1999). Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopatreated L-methyl-4-phenyl-tetrahydropyridine monkeys. Journal of Pharmacology and Experimental Therapeutics 290, 1034-1040. (Pubitemid 29400241)
2. Braak H, Braak E (2000). Pathoanatomy of Parkinson's disease. Journal of Neurology 247 (Suppl. 2), 310-320.
3. Chéremy A, L'hirondel M, Godeheu G, Artand F, et al. (1998). Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Amino Acids 14, 63-68. (Pubitemid 28051153)
4. Cohen J (1998). Statistical Power Analysis for the Behavioural Science, 2nd edn. Lawrence Erlbaum Associates, Hillside, NJ.
5. Dunah AW, Standaert DG (2003). Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. Journal of Neurochemistry 85, 935-943. (Pubitemid 36578625)
6. Fahn S, Elton RL (1987). UPDRS development committee. The United Parkinson's disease rating scale. In: Fahn S, Marsden CD, Caine DB, Goldstein M (Eds), Recent Developments in Parkinson's Disease, vol. 2 (pp. 153-163, 293-304). Florham Park, NJ: Macmillan Healthcare Information.
7. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health.
8. Hallett PJ, Standaert DG (2004). Rationale for and use of NMDA antagonists in Parkinson's disease. Pharmacological Therapeutics 10, 155-174. (Pubitemid 38681014)
9. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, et al. (2004). High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 55, 165-171. (Pubitemid 38367720)
10. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, et al. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 57, 577-585. (Pubitemid 40409697)
11. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
12. Isella V, Melzi P, Grimaldi M, Iurlano S, et al. (2002). Clinical neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Movement Disorders 227, 366-371. (Pubitemid 36041307)
13. Johnson KA, Conn PJ, Niswender CM (2009). Glutamate receptors as therapeutic targets for Parkinson's disease. CNS & Neurological Disorders Drug Targets 8, 475-491.
14. Kantrowitz JT, Ziwich RT, Cornblatt BA, Malhotra AK, et al. (2010). High dose D-serine in the treatment of schizophrenia. Schizophrenia Research 121, 125-130.
15. Kay SR, Opler LA, Fiszbein A (1987). Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, CA: Social and Behavioral Sciences Documents.
16. Mustafa AK, Kim PM, Snyder SH (2004). D-serine as a putative glial neurotransmitter. Neuron Glia Biology 3, 275-281.
17. Nash JE, Brotchie JM (2002). Characterisation of striatal NMDARs involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Movement Disorders 17, 455-466. (Pubitemid 36040956)
18. Nikam SS, Meltzer LT (2002). NR2B selective NMDA receptor antagonists. Current Pharmaceutical Design 8, 845-855. (Pubitemid 34506366)
19. Pluck GC, Brown RG (2002). Apathy in Parkinson's Disease. Journal of Neurology, Neurosurgery and Psychiatry 73, 636-642. (Pubitemid 35448846)
20. Schneider JS, Tinker JP, Van Velson M, Giardiniere M (2000). Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Research 31, 190-194. (Pubitemid 30155856)
21. Shleper M, Kartvelishvily E, Wolosker H (2005). D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. Journal of Neuroscience 25, 9413-9417. (Pubitemid 41464754)
22. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212 (Suppl.), 11-19.
23. Starr MS (1995). Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19, 264-293.
24. Starr MS (1998). Antagonists of glutamate in the treatment of Parkinson's disease: from laboratory to the clinic. Amino Acids 14, 41-42. (Pubitemid 28051149)
25. Stauch Slusher B, Rissolo KC, Jackson PF, Pullan LM (1994). Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. Journal of Neural Transmission-Genetics Section 97, 175-185.